Healthcare: Johnson & Johnson Takes A Shot At Gilead Sciences

<p><span style="font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px;">Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry.</span></p>